Physician profile
Randal S Scholma
NPI 1558574566
$111,379.00
in general payments reported to CMS, 2019-2025
21 companies · $29K in 2025
The $29K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $19K · 2021: $8,398 · 2022: $12K · 2023: $13K · 2024: $16K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $22K · Consulting Fee: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $6,747 · Travel and Lodging: $3,361 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,200 · Education: $83.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $22,039.00 |
| Consulting Fee | $12,500.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,126.00 |
| Food and Beverage | $6,747.43 |
| Travel and Lodging | $3,360.55 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,200.00 |
| Education | $83.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $36,554.53 | 2023-2025 | Auvelity |
| Allergan, INC. | $33,078.20 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $22,235.82 | 2019-2025 | Ingrezza |
| Abbvie INC. | $14,574.51 | 2021-2025 | Vraylar |
| Alkermes, INC. | $714.73 | 2019-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $617.40 | 2019-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $504.08 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $494.43 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $451.30 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $420.04 | 2020-2025 | Caplyta |
| Lundbeck LLC | $411.17 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $366.62 | 2019-2021 | |
| Corium, LLC | $310.15 | 2023-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $140.98 | 2019-2024 | Trintellix |
| Merck Sharp & Dohme LLC | $135.50 | 2019-2023 | Belsomra |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $124.06 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $70.22 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $66.20 | 2019 | |
| Supernus Pharmaceuticals, INC. | $49.59 | 2025 | Qelbree |
| Shire North American Group INC | $35.87 | 2019 | |
| Neuronetics, INC. | $23.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randal Scholma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.